Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17;16(1):1126.
doi: 10.1007/s12672-025-02906-4.

Prognostic value of LncRNA SH3BP5-AS1 in non-small cell lung cancer and its regulatory effect on tumor progression

Cong Meng #  1 , Aihua Zang #  2 , Fengcai Du  3
Affiliations

Prognostic value of LncRNA SH3BP5-AS1 in non-small cell lung cancer and its regulatory effect on tumor progression

Cong Meng et al. Discov Oncol. .

Abstract

Objective: This study aimed to investigate the prognostic significance of SH3BP5-AS1 in non-small cell lung cancer (NSCLC) patients, and also to uncover its function in the progression of NSCLC.

Methods: 100 NSCLC patients were recruited in this study. SH3BP5-AS1 was measured by RT-qPCR. The prognostic significance of SH3BP5-AS1 in NSCLC progression was appraised utilizing the Kaplan-Meier and Cox regression test. CCK-8 was used to detect the proliferative viability of NSCLC cells. The migratory and invasive capabilities of NSCLC cells were evaluated by Transwell assay. The interplay between SH3BP5-AS1 and miR-424-5p was verified by luciferase reporter assay and ENCORI database. The potential target genes of miR-424-5p were inspected by means of bioinformatics analysis.

Results: A reduced SH3BP5-AS1 was manifested in tissues of NSCLC patients and tumor cells. Compared with patients showing SH3BP5-AS1 low-expression, those with SH3BP5-AS1 high-expression possessed a more favorable progression-free survival time. SH3BP5-AS1 might function as an autonomous prognostic biomarker for NSCLC. Upregulation of SH3BP5-AS1 suppressed the proliferation, migration and invasion of NSCLC cells. MiR-424-5p was a downstream target miRNA of SH3BP5-AS1, and luciferase reporter assays verified that SH3BP5-AS1 and miR-424-5p interact. In NSCLC patient tissues, miR-424-5p was upregulated and it exhibited an inverse correlation with SH3BP5-AS1. Elevation of miR-424-5p neutralized the inhibitory effect of SH3BP5-AS1 overexpression on the proliferation, migration, and invasion abilities of NSCLC cells.

Conclusion: SH3BP5-AS1 is involved in NSCLC development by targeting its downstream target miRNA miR-424-5p, and it is a latent prognostic indicator for NSCLC.

Keywords: Biomarker; LncRNA SH3BP5-AS1; MiR-424-5p; Non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
LncRNA SH3BP5-AS1 in tissues of NSCLC patients and tumor cells. SH3BP5-AS1 in NSCLC tissues (A) and cells (B). SH3BP5-AS1 in cancer and normal LUAD (C) or LUSC (D) samples from the ENCORI database. (*P < 0.05, ***P < 0.001 vs. normal group, ***P < 0.001 vs. 16HBE). The data in Figures (A-B) were analyzed by one-way ANOVA/Tukey’s test, and in (C-D), data were analyzed by student’s t‐test
Fig. 2
Fig. 2
Prognostic role of lncRNA SH3BP5-AS1 in NSCLC patients. (A). Kaplan-Meier survival analysis for SH3BP5-AS1 in NSCLC patients. Univariate (B) and multivariate (C) Cox analysis of prognostic factors for HCC
Fig. 3
Fig. 3
Effect of overexpression of SH3BP5-AS1 on proliferation, migration and invasion of CALU-1 and A549 cells. (A). SH3BP5-AS1 in CALU-1 and A549 cells transfected with pcDNA3.1-SH3BP5-AS1. Effect of overexpression of SH3BP5-AS1 on the proliferation of CALU-1 (B) and A549 (C) cells. Effect of overexpression of SH3BP5-AS1 in CALU-1 (D) and A549 (E) cells on migration and invasion. (***P < 0.001 vs. blank group, ###P < 0.001 vs. pcDNA3.1 group). The data in Figures (A-E) were analyzed by two-way ANOVA/Tukey’s test
Fig. 4
Fig. 4
Interaction of lncRNA SH3BP5-AS1 with miR-424-5p. (A) Binding sites of SH3BP5-AS1 with miR-424-5p. (B) Luciferase reporter assay verified the interaction of SH3BP5-AS1 with miR-424-5p. (C) MiR-424-5p in NSCLC tissues. (D) Correlation analysis of SH3BP5-AS1 with miR-424-5p. MiR-424-5p in cancer and normal LUAD (E) or LUSC (F) samples from the ENCORI database. (***P < 0.001 vs. mimic-NC, ***P < 0.001 vs. normal group, ###P < 0.001 vs. inhibitor-NC). The data in Figure (B) was analyzed by two-way ANOVA/Tukey’s test, and in (C, E and F), data were analyzed by student’s t‐test
Fig. 5
Fig. 5
Effect of lncRNA SH3BP5-AS1 on cell function by targeting miR-424-5p. Effect of overexpression of SH3BP5-AS1 and miR-424-5p on proliferation of CALU-1 (A) and A549 (B) cells. Effects of overexpression of SH3BP5-AS1 and miR-424-5p in CALU-1 (C) and A549 (D) cells on migration and invasion. (***P < 0.001 vs. pcDNA3.1 group, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. mimic-NC). The data in Figures (A–D) were analyzed by two-way ANOVA/Tukey’s test
Fig. 6
Fig. 6
Prediction and functional characterization of miR-424-5p target genes. A Veen diagram. B GO analysis outcomes. C. KEGG enrichment analysis
See this image and copyright information in PMC

References

    1. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–67. - DOI - PubMed
    1. Basumallik N, Agarwal M. Small cell lung cancer. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Manuj Agarwal declares no relevant financial relationships with ineligible companies. 2024.
    1. Siegel RL, Miller KD, Jemal A, Cancer statistics. 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. 10.1002/ijc.29210. - DOI - PubMed
    1. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535–54. 10.1016/S0140-6736(21)00312-3. - DOI - PubMed

LinkOut - more resources